MicroRNAs Associated with Epithelial-Mesenchymal Transition Can Be Targeted to Inhibit Peritoneal Dissemination of Human Scirrhous Gastric Cancers
Conclusions: EMT-associated miRNAs such as miR-200c and miR-141 and their target genes ZEB1/ZEB2 have good potential for antiperitoneal dissemination therapy in patients with scirrhous gastric cancers.Pathobiology (Source: Pathobiology)
Source: Pathobiology - May 30, 2018 Category: Pathology Source Type: research
Metaplastic Breast Cancer Masquerading as Liposarcoma of the Breast: A Case Report following Oncoplastic Treatment
Mammary liposarcoma is among the rarest of breast tumours. Here we report the presentation, macroscopic, microscopic, and immunohistochemical features of an extremely rare case of metaplastic carcinoma with extensive pleomorphic liposarcomatous differentiation. A 47-year-old woman presented with bilateral grade III breast ptosis and a 3 × 4 cm mass in the lower outer quadrant of the left breast. Mammography and ultrasound confirmed a well-defined mass. A core biopsy performed was diagnosed as pleomorphic liposarcoma. Microscopically, this was a well-defined, lobulated tumour comprising solid sheets of large pleomorphic an...
Source: Pathobiology - May 29, 2018 Category: Pathology Source Type: research
Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities
Conclusions: This study shows divergence in miR expression in breast cancers from different ethnic groups, and suggests that specific genetic variants in miR genes may affect breast cancer risk in these groups. Predicted targets of these miRs may uncover useful biomarkers that could have clinical value in breast cancers in different ethnic groups.Pathobiology (Source: Pathobiology)
Source: Pathobiology - May 29, 2018 Category: Pathology Source Type: research
The Molecular Pathology of Myelodysplastic Syndrome
The diagnosis and classification of myelodysplastic syndromes (MDS) are based on cytomorphology and cytogenetics (WHO classification). Prognosis is best defined by the Revised International Prognostic Scoring System (IPSS-R). In recent years, an increasing number of molecular aberrations have been discovered. They are already included in the classification (e.g.,SF3B1) and, more importantly, have emerged as valuable markers for better classification, particularly for defining risk groups. Mutations in genes such asSF3B1 andIDH1/2 have already had an impact on targeted treatment approaches in MDS.Pathobiology (Source: Pathobiology)
Source: Pathobiology - May 29, 2018 Category: Pathology Source Type: research
Title Page / Table of Contents
Pathobiology 2018;85:1 –4 (Source: Pathobiology)
Source: Pathobiology - May 7, 2018 Category: Pathology Source Type: research
Author Index
Pathobiology 2018;85:155 (Source: Pathobiology)
Source: Pathobiology - May 7, 2018 Category: Pathology Source Type: research
Subject Index
Pathobiology 2018;85:156 (Source: Pathobiology)
Source: Pathobiology - May 7, 2018 Category: Pathology Source Type: research
---
Pathobiology 2018;85:1 –4 (Source: Pathobiology)
Source: Pathobiology - May 3, 2018 Category: Pathology Source Type: research
---
Pathobiology 2018;85:155 (Source: Pathobiology)
Source: Pathobiology - May 3, 2018 Category: Pathology Source Type: research
---
Pathobiology 2018;85:156 (Source: Pathobiology)
Source: Pathobiology - May 3, 2018 Category: Pathology Source Type: research
Clinical Relevance of Intra-Tumour Heterogeneity
Pathobiology (Source: Pathobiology)
Source: Pathobiology - April 11, 2018 Category: Pathology Source Type: research
Heterogeneity in Lung Cancer
Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed cancers. Diagnostic challenges are deeply related to the development of personalized therapy and molecular and precise histological characterizations of lung cancer. When addressing these features, it is very important to acknowledge the issue of tumour heterogeneity, as it imposes several questions. First of all, lung cancer is a very heterogeneous disease, at a cellular and histological level. Cellular and histological heterogeneity are addressed with emphasis on the diagnosis, pre-neoplastic lesions, and cell origin, trying to con...
Source: Pathobiology - April 10, 2018 Category: Pathology Source Type: research
Proteomic Profiling of Diffuse Large B-Cell Lymphomas
Conclusion: A validation study of 3 selected proteins (BiP/Grp78, Hsp90, and cyclin B2) showed the enhanced expression in non-GC DLBCL, supporting the proteomics data.Pathobiology (Source: Pathobiology)
Source: Pathobiology - April 4, 2018 Category: Pathology Source Type: research
Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine
Breast cancer (BC) displays striking clinical, morphological, and behavioural diversity within a single tumour and between tumours. Currently, mounting evidence indicates that the morphological heterogeneity of BC reflects an underlying spectrum of genetic and epigenetic portraits that control BC behaviour. Further understanding of BC heterogeneity will have an impact, not only on the routine diagnostic practices but also on patients' management decisions. Phenomena like diagnostic inconsistencies and therapeutic resistance, both primary and acquired, could be attributed, at least in part, to tumour heterogeneity within th...
Source: Pathobiology - February 9, 2018 Category: Pathology Source Type: research
Metabolite Levels in Paediatric Brain Tumours Correlate with Histological Features
Conclusion: Metabolite levels in children's brain tumours measured by MRS are closely associated with key histological features routinely assessed by histopathologists in the diagnostic process. This further elucidates our understanding of this important non-invasive diagnostic tool and strengthens our understanding of the relationship between metabolites and histological features.Pathobiology (Source: Pathobiology)
Source: Pathobiology - February 9, 2018 Category: Pathology Source Type: research
